利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.013 秒)

    Crystalline rosuvastatin calcium trihydrate
    3.
    发明公开
    Crystalline rosuvastatin calcium trihydrate 有权
    Kristallines Rosuvastatin Calzium-Trihydrat

    公开(公告)号：EP2752407A1

    公开(公告)日：2014-07-09

    申请号：EP14162586.3

    申请日：2010-01-14

    申请人： Krka Tovarna Zdravil, D.D., Novo Mesto

    发明人： Benkic, Primoz ,  Bevk, David ,  Lenarsic, Roman ,  Zupancic, Silvo ,  Vajs, Anamarija ,  Jakse, David

    IPC分类号： C07D239/42

    CPC分类号： C07D239/42

    摘要： The invention relates to a process for the preparation of a HMG - CoA reductase inhibitor such as rosuvastatin, as well as intermediates useful in such process. The invention also relates to salts of HMG-CoA reductase inhibitors and processes for preparing same as well as processes for preparing pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.

    摘要翻译： 本发明涉及制备HMG-CoA还原酶抑制剂如罗苏伐他汀的方法，以及在该方法中有用的中间体。 本发明还涉及HMG-CoA还原酶抑制剂的盐及其制备方法以及制备HMG-CoA还原酶抑制剂的药学上可接受的盐的方法。

    Pharmaceutical formulation of duloxetine hydrochloride
    4.
    发明公开
    Pharmaceutical formulation of duloxetine hydrochloride 审中-公开
    Pharmazutische Zubereitung Enhaltend Duloxetin Hydrochlorid

    公开(公告)号：EP2308864A1

    公开(公告)日：2011-04-13

    申请号：EP10186667.1

    申请日：2007-02-16

    申请人： KRKA, tovarna zdravil, d.d., Novo mesto

    发明人： Stimac, Anton ,  Zajc, Natalija ,  Vajs, Anamarija ,  Jakse, Renata ,  Zupet, Rok

    IPC分类号： C07D333/20 ,  A61K9/50 ,  A61K31/381

    CPC分类号： A61K9/5078 ,  A61K9/5026 ,  A61K31/381 ,  C07D333/20

    摘要： The present invention relates to polymorphic forms of duloxetine hydrochloride, especially (duloxetine HCl), which are characterized by an X-ray diffraction pattern with peaks (2θ):9.6, 13.9, 18.0, 18.8, 19.2, 20.8, 27.4, 27.9 (designated form A) or an X-ray diffraction pattern with characteristic peaks (2θ): 12.0, 14.8, 19.8, 21.3, 21.6, 22.1, 22.4, 23.1, 24.1 (designated form T). The present invention also pertains to processes for the preparation of form A and form T, which involves dissolving duloxetine hydrochloride in particular solvents and cooling the solution to obtain crystals, that are dried.

    摘要翻译： 本发明涉及度洛西汀盐酸盐，特别是（度洛西汀盐酸盐）的多晶型物，其特征在于具有峰（2°）：9.6,13.9,18.0,18.8,19.2,20.8,27.4,27.9（的X射线衍射图 指定形式A）或具有特征峰（2¸）：12.0,14.8,19.8,21.3,21.6,22.1,22.4,23.1,24.1（以T表示）的X射线衍射图。 本发明还涉及制备形式A和形式T的方法，其包括将度洛西汀盐酸盐溶解在特定溶剂中并冷却溶液以获得待干燥的晶体。

    Crystalline forms of duloxetine hydrochloride and processes for their preparation
    5.
    发明公开
    Crystalline forms of duloxetine hydrochloride and processes for their preparation 审中-公开
    Kristalline Formen von度洛西汀盐酸盐和Verfahren zu deren Herstellung

    公开(公告)号：EP1820800A1

    公开(公告)日：2007-08-22

    申请号：EP06003244.8

    申请日：2006-02-17

    申请人： KRKA, tovarna zdravil, d.d., Novo mesto

    发明人： Stimac, Anton ,  Jakse, Renata ,  Zajc, Natalija ,  Zupet, Rok ,  Vajs, Anamarija

    IPC分类号： C07D333/20 ,  A61K31/381

    CPC分类号： A61K9/5078 ,  A61K9/5026 ,  A61K31/381 ,  C07D333/20

    摘要： The present invention relates to polymorphic forms of duloxetine hydrochloride, especially (duloxetine HCl), which are characterized by an X-ray diffraction pattern with peaks (2θ):9.6, 13.9, 18.0, 18.8, 19.2, 20.8, 27.4, 27.9 (designated form A) or an X-ray diffraction pattern with characteristic peaks (2θ): 12.0, 14.8, 19.8, 21.3, 21.6, 22.1, 22.4, 23.1, 24.1 (designated form T). The present invention also pertains to processes for the preparation of form A and form T, which involves dissolving duloxetine hydrochloride in particular solvents and cooling the solution to obtain crystals, that are dried.

    摘要翻译： 本发明涉及度洛西汀盐酸盐，特别是（度洛西汀盐酸盐）的多晶型物，其特征在于具有峰（2°）：9.6,13.9,18.0,18.8,19.2,20.8,27.4,27.9（的X射线衍射图 指定形式A）或具有特征峰（2¸）：12.0,14.8,19.8,21.3,21.6,22.1,22.4,23.1,24.1（以T表示）的X射线衍射图。 本发明还涉及制备形式A和形式T的方法，其包括将度洛西汀盐酸盐溶解在特定溶剂中并冷却溶液以获得待干燥的晶体。